Pacira Biosciences inc (PCRX) - News Archive

Pacira BioSciences, Inc. (Nasdaq: PCRX), a prominent biopharmaceutical company recognized for its dedication to developing innovative non-opioid pain management therapies, has taken legal action to protect its proprieta...

Osteoarthritis (OA) is a progressive degenerative disease characterized by the breakdown of cartilage and underlying bone, leading to significant pain and functional limitations. The potential for gene therapy to offer...

Pacira BioSciences: A Strategic Move Towards Strengthening Shareholder Value Amidst ChallengesIn a rapidly evolving biopharmaceutical landscape, Pacira BioSciences, Inc. (Nasdaq: PCRX) has made significant strides to en...

Pacira BioSciences Strengthens Workforce and Innovations with Inducement Grants Amidst Market Growth and Legal ChallengesBRISBANE, Calif. April 11, 2025 Pacira BioSciences, Inc. (Nasdaq: PCRX), a trailblazer in developi...

Breaking News Pacira Biosciences Advances to Become Innovative Biopharmaceutical OrganizationIn a significant development for the biopharmaceutical landscape, Pacira Biosciences Inc. (NASDAQ: PCRX) has unveiled its ambi...

Shareholders Alerted as Levi & Korsinsky Announces Lead Plaintiff Deadline in Pacira BioSciences Lawsuit New York, February 21, 2025 Levi & Korsinsky, LLP has issued a notification to investors in Pacira BioSciences, In...

In a recent press release dated February 6, 2025, Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in non-opioid pain management solutions, shared an important update regarding its human resources and corporate strateg...

In a strategic move signaling its commitment to innovation and growth, Pacira Biosciences has announced new five-year objectives designed to expedite its transformation into a leading biopharmaceutical entity. With a ro...

: This article aims to synthesize findings from recent data presented by Pacira Biosciences at the ACR Convergence annual meeting regarding the long-term safety and efficacy of their investigational product, PCRX-201, f...

: Pacira BioSciences, an industry leader in non-opioid pain management, has made a significant advancement in its billing and reimbursement processes for EXPAREL, a bupivacaine liposome injectable suspension. Following...

In a significant advancement for the treatment of moderate to severe osteoarthritis of the knee, Pacira BioSciences, Inc. (NASDAQ: PCRX), a leader in innovative non-opioid pain management solutions, has announced the fo...

TAMPA, Fla. Sept. 09, 2024 - Pacira BioSciences, Inc. a leading player dedicated to non-opioid pain management and regenerative health solutions, recently announced the provision of inducement awards to 17 new employees...

In recent weeks, Pacira BioSciences Inc (NASDAQ: PCRX) has experienced a decline in its stock performance, trailing behind the overall market. This downtrend can be attributed to various factors, including recent analys...

Pacira BioSciences is a biopharmaceutical company that focuses on the development and commercialization of innovative products for pain management and enhanced surgical care. The company is well-known for its flagship p...

Pacira Releases Groundbreaking Study: EXPAREL as a Sciatic Nerve Block Revolutionizes Pain Management after BunionectomiesIn recent years, Pacira BioSciences has been at the forefront of developing innovative solutions...

In an era marked by the opioid crisis, the need for reliable non-opioid pain management and regenerative health solutions has never been more urgent. Consequently, the annunciation of a national group purchasing agreeme...